IN Brief:
- Formo reports receipt of an FDA no-questions letter linked to GRAS notice 1312 for recombinant αS1-casein.
- The notified use covers cheese analogues at up to 25g per 100g, excluding infant formula and USDA-regulated products.
- The ingredient remains a milk allergen; the company plans further GRAS work before expanding into additional food categories.
Formo says its precision-fermented Enhanced Casein has received a no-questions response from the US Food and Drug Administration for a specified use in cheese alternatives. The development follows a Generally Recognized as Safe notification covering recombinant αS1-casein produced through fermentation. It advances the ingredient’s route to US food manufacturing, but the scope is defined by the notified ingredient and the intended applications rather than an unrestricted approval of every possible use.
FDA GRAS notice 1312 identifies the ingredient as recombinant αS1-casein and states an intended use of up to 25 grams per 100 grams in cheese analogues. Infant formula and products regulated by the US Department of Agriculture are excluded. Formo Foods GmbH and NewMilkBuzz BV are named as joint notifiers, reflecting development undertaken before Formo and Belgian company Those Vegan Cowboys began pursuing their casein businesses independently. Formo reports that the agency’s review has concluded with a no-questions letter.
Casein is a principal protein in cow’s milk, contributing to the structures that give cheese its texture, melt and emulsification properties. Interactions among casein, water and fat are difficult to reproduce when an alternative recipe uses proteins with different molecular behaviour. Precision fermentation can produce a specified milk protein through microbial production instead of separating it from milk. Formo is developing the resulting ingredient for manufacturers seeking dairy-like functionality in formulations without conventional dairy inputs.
Enhanced Casein is produced using a microorganism engineered to make the target αS1-casein during fermentation. The protein must subsequently be recovered and purified to meet the specification used for the safety assessment. At commercial scale, repeatable fermentation batches and downstream separation are necessary to control identity, purity, residual process materials and consistency. Those requirements connect the notified ingredient specification to what a food processor can incorporate into a finished product.
A GRAS notification describes a substance and specific intended uses supported by a safety dossier. The FDA reviews the notifier’s conclusion and may respond that it has no questions about that conclusion under the notified conditions. This process differs from a general product approval covering all potential uses. Formo’s reported response therefore relates to the defined cheese analogue application and concentration in notice 1312; other food categories require their own suitable regulatory basis.
Formo is also pursuing protein drinks and nutrition products, where levels of consumption, preparation methods and formulations differ from cheese alternatives. The company intends to submit additional GRAS material to support broader applications. A high-protein drink, for instance, may require different ingredient concentrations and stability testing from a cheese analogue. The precise conditions of use will determine how the company can commercialise those products in the United States.
Producing casein without milking cows does not remove its milk-protein allergen properties. Formo’s ingredient is described as lactose-free, but lactose intolerance is distinct from an immune reaction to casein. Foods containing the protein must be managed accordingly through allergen assessment, handling controls and the relevant labelling requirements. The production method may change the source and supply arrangements of casein, while its allergenic identity remains a constraint for finished products.
Formo has established US commercial activity through Formo Foods Inc and partners while preparing to scale production with contract manufacturers. Its earlier work included laboratory and pilot-scale development in Germany. Expansion requires consistent fermentation output, downstream protein recovery, documented hygiene controls and material specifications that customers can use in product validation. Contract production will need to deliver that consistency at the volumes and schedules expected by food manufacturers adopting the ingredient. Differences between pilot fermentation and commercial equipment may also require renewed checks of downstream protein concentration and final material specification before batches are released to customers.
The company’s SupplySide Global demonstrations in Las Vegas include a clear protein beverage and a high-protein cold foam for coffee. These trials illustrate possible performance in recipes beyond the notified cheese use. Dispersibility, foaming, mouthfeel and storage stability require assessment under each recipe’s processing and serving conditions. Such development work can continue while the company prepares the separate regulatory submissions needed for additional commercial applications.
The reported FDA response gives Formo a defined regulatory basis for its notified cheese analogue use. Manufacturers adopting Enhanced Casein must still match that use to their recipe specifications, allergen controls and ingredient supply agreements. Formo’s planned expansion into other foods will depend on further safety documentation, consistent production at greater scale and evidence that the protein delivers the intended functionality in each manufacturing process.
